HSPB11 is a Prognostic Biomarker Associated with Immune Infiltrates in Hepatocellular Carcinoma

Overview

Journal Int J Gen Med

Publisher Dove Medical Press

Specialty General Medicine

Date 2022 Apr 21

PMID 35444459

Authors

Hui Liu

Mei Yang

Zhiwei Dong

Affiliations

Soon will be listed here.

Abstract

Purpose: Heat shock proteins (HSPs) play important roles in oncogenesis and malignant progression. HSPB11 is highly expressed in many malignant tumors, but research on its role in hepatocellular carcinoma (HCC) is insufficient.

Patients And Methods: A comprehensive analysis of HSPB11 in HCC was performed based on data of patients with HCC and those from online public databases.

Results: HSPB11 was overexpressed in HCC, with a high discrimination ability between tumor and normal tissues (area under the curve =0.923). HSPB11 overexpression correlated with advanced tumor stage, poorer tumor differentiation, and worse prognosis and was an independent risk factor for HCC prognosis. The nomogram and calibration models composed of HSPB11, T stage, and M stage had good abilities to predict the 1-, 3-, and 5-year survival rates of patients. HSPB11 was determined to be involved in multiple oncogenic processes, including cell cycle checkpoints, the G2M checkpoint, E2F targets, Rho GTPases, and KRAS signaling. HSPB11 expression was related to immune cell infiltration, especially that of Th2 cells and dendritic cells.

Conclusion: HSPB11 is involved in oncogenesis and immune regulation in HCC and is a potential prognostic biomarker and therapeutic target.

Citing Articles

Predictive and Prognostic Relevance of Tumor-Infiltrating Immune Cells: Tailoring Personalized Treatments against Different Cancer Types.

Dakal T, George N, Xu C, Suravajhala P, Kumar A Cancers (Basel). 2024; 16(9).

PMID: 38730579 PMC: 11082991. DOI: 10.3390/cancers16091626.

Establishment and Clinical Application of the Nomogram Related to Risk or Prognosis of Hepatocellular Carcinoma: A Review.

Wang X, Zhao M, Zhang C, Chen H, Liu X, An Y J Hepatocell Carcinoma. 2023; 10:1389-1398.

PMID: 37637500 PMC: 10460189. DOI: 10.2147/JHC.S417123.

References

Kirbach B, Golenhofen N . Differential expression and induction of small heat shock proteins in rat brain and cultured hippocampal neurons. J Neurosci Res. 2010; 89(2):162-75. DOI: 10.1002/jnr.22536. View

Paulovich A, Toczyski D, Hartwell L . When checkpoints fail. Cell. 1997; 88(3):315-21. DOI: 10.1016/s0092-8674(00)81870-x. View

Wong C, Wei L, Au S, Fan D, Zhou Y, Tsang F . MiR-200b/200c/429 subfamily negatively regulates Rho/ROCK signaling pathway to suppress hepatocellular carcinoma metastasis. Oncotarget. 2015; 6(15):13658-70. PMC: 4537040. DOI: 10.18632/oncotarget.3700. View

Schipilliti F, Garajova I, Rovesti G, Balsano R, Piacentini F, Dominici M . The Growing Skyline of Advanced Hepatocellular Carcinoma Treatment: A Review. Pharmaceuticals (Basel). 2021; 14(1). PMC: 7827379. DOI: 10.3390/ph14010043. View

Sharma A, Upadhyay A, Bhat M . Inhibition of Hsp27 and Hsp40 potentiates 5-fluorouracil and carboplatin mediated cell killing in hepatoma cells. Cancer Biol Ther. 2009; 8(22):2106-13. DOI: 10.4161/cbt.8.22.9687. View

Cheng W, Li M, Jiang Y, Zhang C, Cai J, Wang K . Association between small heat shock protein B11 and the prognostic value of MGMT promoter methylation in patients with high-grade glioma. J Neurosurg. 2015; 125(1):7-16. DOI: 10.3171/2015.5.JNS142437. View

Budhu A, Forgues M, Ye Q, Jia H, He P, Zanetti K . Prediction of venous metastases, recurrence, and prognosis in hepatocellular carcinoma based on a unique immune response signature of the liver microenvironment. Cancer Cell. 2006; 10(2):99-111. DOI: 10.1016/j.ccr.2006.06.016. View

Franck E, Madsen O, van Rheede T, Ricard G, Huynen M, de Jong W . Evolutionary diversity of vertebrate small heat shock proteins. J Mol Evol. 2004; 59(6):792-805. DOI: 10.1007/s00239-004-0013-z. View

Farkas R, Pozsgai E, Bellyei S, Cseke L, Szigeti A, Vereczkei A . Correlation between tumor-associated proteins and response to neoadjuvant treatment in patients with advanced squamous-cell esophageal cancer. Anticancer Res. 2011; 31(5):1769-75. View

10.

Bray F, Ferlay J, Soerjomataram I, Siegel R, Torre L, Jemal A . Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018; 68(6):394-424. DOI: 10.3322/caac.21492. View

11.

Lang S, Moser C, Fichnter-Feigl S, Schachtschneider P, Hellerbrand C, Schmitz V . Targeting heat-shock protein 90 improves efficacy of rapamycin in a model of hepatocellular carcinoma in mice. Hepatology. 2008; 49(2):523-32. DOI: 10.1002/hep.22685. View

12.

Dudek A, Martin S, Garg A, Agostinis P . Immature, Semi-Mature, and Fully Mature Dendritic Cells: Toward a DC-Cancer Cells Interface That Augments Anticancer Immunity. Front Immunol. 2013; 4:438. PMC: 3858649. DOI: 10.3389/fimmu.2013.00438. View

13.

Llovet J, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc J . Sorafenib in advanced hepatocellular carcinoma. N Engl J Med. 2008; 359(4):378-90. DOI: 10.1056/NEJMoa0708857. View

14.

Challen C, Guo K, Collier J, Cavanagh D, Bassendine M . Infrequent point mutations in codons 12 and 61 of ras oncogenes in human hepatocellular carcinomas. J Hepatol. 1992; 14(2-3):342-6. DOI: 10.1016/0168-8278(92)90181-n. View

15.

Chen K, Lin S, Zhou L, Xie H, Zhou W, Taki-Eldin A . Selective recruitment of regulatory T cell through CCR6-CCL20 in hepatocellular carcinoma fosters tumor progression and predicts poor prognosis. PLoS One. 2011; 6(9):e24671. PMC: 3173477. DOI: 10.1371/journal.pone.0024671. View

16.

Fu Y, Li J, Feng M, Yang X, Wang Y, Zhang Y . Cytohesin-3 is upregulated in hepatocellular carcinoma and contributes to tumor growth and vascular invasion. Int J Clin Exp Pathol. 2014; 7(5):2123-32. PMC: 4069877. View

17.

Calderwood S, Khaleque M, Sawyer D, Ciocca D . Heat shock proteins in cancer: chaperones of tumorigenesis. Trends Biochem Sci. 2006; 31(3):164-72. DOI: 10.1016/j.tibs.2006.01.006. View

18.

Azad A, Zoubeidi A, Gleave M, Chi K . Targeting heat shock proteins in metastatic castration-resistant prostate cancer. Nat Rev Urol. 2014; 12(1):26-36. DOI: 10.1038/nrurol.2014.320. View

19.

Filley A, Dey M . Dendritic cell based vaccination strategy: an evolving paradigm. J Neurooncol. 2017; 133(2):223-235. PMC: 5532060. DOI: 10.1007/s11060-017-2446-4. View

20.

Ischia J, So A . The role of heat shock proteins in bladder cancer. Nat Rev Urol. 2013; 10(7):386-95. DOI: 10.1038/nrurol.2013.108. View